On January 18, according to the press conference on the adjustment of the 2022 National Medical Insurance Drug List, this medical insurance negotiation fully supports the treatment of new coronavirus infection. For the third consecutive year, new crown treatment drugs have been included as a condition for admission to the national medical insurance catalog. Two drugs, including Azivudine Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance catalog after price reductions through negotiations. Among the 25 marketed drugs involved in the tenth edition of the new coronavirus infection diagnosis and treatment plan, 21 varieties have been officially included in the national medical insurance catalog. This year, a total of 3 new crown treatment drugs were included in the negotiations, among which Azvudine Tablets and Qingfei Paidu Granules were successfully negotiated. After several rounds of negotiations, Azvudine, an oral drug for the treatment of COVID-19, was finally successfully negotiated at 11.58 yuan and officially included in the medical insurance catalogue. | Related Reading (Wall Street Insights)
This article is reproduced from: https://www.fortunechina.com/jingxuan/26159.htm
This site is only for collection, and the copyright belongs to the original author.